17 completed, 2 unknown, 1 recruiting. 20 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 20 | Completed 17, Unknown 2, Recruiting 1 |
| Phase 2 | 5 | Completed 2, Unknown 2, Recruiting 1 |
Follow End-Stage Renal Disease: new trials by email Literature Review of End-Stage Renal Disease trials Research Report on End-Stage Renal Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006) MK-2828 - Chronic Kidney Failure, End-Stage Renal Disease | Phase 1 | Completed | Merck Sharp & Dohme LLC | 18 | 2026-03-02 | 2026-09-15 |
| CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk Ex Vivo CRISPR-Cas9 Gene Editing of Donor Kidney, Kidney Transplantation with Standard Care - End-Stage Renal Disease, End Stage Renal Disease on Dialysis | Phase 1 / Phase 2 | Recruiting | AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC | 90 | 2025-06-01 | 2025-07-08 |
| A Study of MK-2060 in Participants With Chronic and/or End-Stage Kidney Disease (MK-2060-011) MK-2060, Placebo - End-Stage Renal Disease, End-Stage Kidney Disease | Phase 1 | Completed | Merck Sharp & Dohme LLC | 14 | 2023-02-08 | 2025-09-10 |
| MK-2060 and Clopidogrel Co-administration Safety and Tolerability Study in Participants With End-Stage Renal Disease (ESRD) (MK-2060-008) MK-2060 - End-Stage Renal Disease, Kidney Failure, Chronic | Phase 1 | Completed | Merck Sharp & Dohme LLC | 12 | 2022-05-30 | 2024-10-17 |
| Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant Clazakizumab - Kidney Failure, Chronic, End-Stage Renal Disease | Phase 1 / Phase 2 | Completed | Stanley Jordan, MD | 20 | 2018-02-27 | 2026-10-30 |
| A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis Rivaroxaban 15 mg - End-Stage Renal Disease | Phase 1 | Completed | Janssen Research & Development, LLC | 16 | 2015-01-01 | 2017-01-24 |
| Chinese Medicine on Deferring Dialysis Initiation CM therapies, CKD-related management - End-Stage Renal Disease | Phase 1 / Phase 2 | Unknown | Guangdong Provincial Hospital of Traditional Chinese Medicine | 875 | 2014-07-01 | 2019-12-26 |
| Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease Carfilzomib - Relapsed Multiple Myeloma, End-stage Renal Disease | Phase 1 | Completed | Amgen | 26 | 2014-01-01 | 2017-05-02 |
| PK of Serelaxin in Severe Renal Impairment and ESRD Serelaxin - Renal Failure, Chronic, End-Stage Renal Disease | Phase 1 | Completed | Novartis Pharmaceuticals | 36 | 2013-08-01 | 2020-12-21 |
| Safety and Efficacy of a Vascular Prosthesis for Hemodialysis Access in Patients With End-Stage Renal Disease HAVG - End-stage Renal Disease, Kidney Failure, Chronic | Phase 1 | Completed | Humacyte, Inc. | 20 | 2013-05-23 | 2022-08-19 |
| Treatment of Children With Kidney Transplants by Injection of CD4+CD25+FoxP3+ T Cells to Prevent Organ Rejection CD4+CD25+CD127lowFoxP3+ T regulatory cells injection, Alemtuzumab, Mycophenolate mofetil - End-Stage Renal Disease, Kidney Failure | Phase 1 / Phase 2 | Unknown | Pirogov Russian National Research Medical University | 30 | 2011-10-01 | 2011-11-18 |
| Study to Evaluate Daptomycin Given During Dialysis and After Dialysis daptomycin - End-stage Renal Disease, Renal Failure Chronic Requiring Hemodialysis | Phase 1 | Completed | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 16 | 2009-04-29 | 2018-02-06 |
| Safety Study to Evaluate Daptomycin in Non-infected Adults Who Are Either on Hemodialysis or Continuous Ambulatory Peritoneal Dialysis (MK-3009-021) daptomycin - End-Stage Renal Disease | Phase 1 | Completed | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 12 | 2007-08-12 | 2018-01-09 |
| Effects of N-acetylcysteine on Muscle Fatigue in Hemodialysis N-acetylcysteine, placebo - End-Stage Renal Disease, Dialysis | Phase 1 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 30 | 2007-03-01 | 2010-03-03 |
| A Novel Catheter Lock Solution for Treatment of Tunneled Hemodialysis Catheter-Associated Bacteremia catheter lock solution consisting of N-acetylcystein, tigecycline and heparin - End-Stage Renal Disease, Hemodialysis Catheter-associated Infection | Phase 1 | Completed | University of California, San Diego | 18 | 2006-10-01 | 2019-10-09 |
| Pharmacokinetics of Somatropin in Patients With End Stage Renal Disease Receiving Chronic Haemodialysis somatropin - Chronic Kidney Disease, End-Stage Renal Disease | Phase 1 | Completed | Novo Nordisk A/S | 21 | 2005-06-01 | 2017-01-24 |
| Simultaneous Islet-Kidney Transplantation in Patients of Type 1 Diabetes With End-stage Renal Disease simultaneous islet-kidney transplantation - Type 1 Diabetes Mellitus, End-stage Renal Disease | Phase 1 / Phase 2 | Completed | Fuzhou General Hospital | 7 | 2005-06-01 | 2011-09-16 |
| Reducing the Risk of Transplant Rejection: Simultaneous Kidney and Bone Marrow Transplant Conditioning Regimen - End-stage Renal Disease, Renal Transplantation | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 5 | 2003-06-01 | 2017-12-27 |
| Tacrolimus Versus Cyclophosphamide as Treatment for Lupus Nephritis Tacrolimus, cyclophosphamide - SLE, Lupus Nephritis | Phase 1 | Completed | Zhejiang University | 40 | 2003-03-01 | 2011-08-23 |
| Pharmacokinetics And Dialysability Of CP-690,550 In Subjects With End-Stage Renal Disease CP-690,550 - End-Stage Renal Disease, Hemodialysis | Phase 1 | Completed | Pfizer | 12 | 2003-02-01 | 2012-12-18 |
Kidney Failure, Chronic (20) · Renal Insufficiency (6) · Renal Insufficiency, Chronic (3) · Kidney Diseases (2) · Carcinoma, Renal Cell (1) · Diabetes Mellitus, Type 1 (1) · Lupus Nephritis (1) · Multiple Myeloma (1) · Rejection, Psychology (1) · Thrombosis (1) · Urologic Diseases (1)
Chronic Disease (20) · Disease Attributes (20) · Female Urogenital Diseases (20) · Female Urogenital Diseases and Pregnancy Complications (20) · Male Urogenital Diseases (20) · Pathologic Processes (20) · Pathological Conditions, Signs and Symptoms (20) · Urogenital Diseases (20) · Urologic Diseases (19) · Kidney Diseases (18) · Renal Insufficiency, Chronic (17) · Renal Insufficiency (14) · Immune System Diseases (3) · Autoimmune Diseases (2) · Cardiovascular Diseases (2)
Daptomycin (2) · Kidney Transplantation (2) · Tacrolimus (2) · Acetylcysteine (1) · Alemtuzumab (1) · Cell- and Tissue-Based Therapy (1) · Complementary Therapies (1) · Cyclophosphamide (1) · Cyclosporine (1) · Everolimus (1) · Heparin (1) · Human Growth Hormone (1) · Medicine, Chinese Traditional (1) · Mycophenolic Acid (1) · Rivaroxaban (1)
Merck Sharp & Dohme LLC (3) · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (2) · AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC (1) · Amgen (1) · Fuzhou General Hospital (1) · Guangdong Provincial Hospital of Traditional Chinese Medicine (1) · Humacyte, Inc. (1) · Janssen Research & Development, LLC (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Novartis Pharmaceuticals (1) · Novo Nordisk A/S (1) · Pfizer (1) · Pirogov Russian National Research Medical University (1) · Stanley Jordan, MD (1)
United States (12) · China (3) · Germany (2) · Australia (1) · Canada (1) · Israel (1) · Romania (1) · Russia (1)
A. Benedict Cosimi, MD (1) · Alistair Wheeler, MD, MFPM (1) · David H. Sachs, MD (1) · Jianghua Chen, MD (1) · Jianming Tan, professor (1) · Kirsten L Johansen, MD (1) · Lynda H Szczech, MD, MSCE (1) · Michael M. Kaabak, M.D. Ph.D. (1) · Ping Li, PhD (1)
PMID 17634080, PMID 18216355, PMID 18633105, PMID 18643743, PMID 21176752, PMID 24030917, PMID 27203778, PMID 37322595, PMID 37651553, PMID 37916745
2005 (1), R21DK077350 (1)